BLR(DE3)pLysS Competent Cells - Novagen

Genotype: F^-ompT hsdS_B(r_B^- m_B^-) gal dcm (DE3) Δ(srl-recA)306::Tn10 pLysS (Cam^R, Tet^R)





This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.

BLR is a recA^- derivative of BL21 that improves plasmid monomer yields and may help stabilize target plasmids containing repetitive sequences or whose products may cause the loss of the DE3 prophage (1, 2).

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

pLysS strains express T7 lysozyme, which further suppresses basal expression of T7 RNA polymerase prior to induction, thus stabilizing pET recombinants encoding target proteins that affect cell growth and viability.

BLR is a recA derivative of BL21 that improves plasmid monomer yields and may help stabilize target plasmids containing repetitive sequences. T7 lysozyme expression suppresses basal T7 expression.

0.4 ml1 mlComponent

•2 × 0.2 ml5 × 0.2 mlBLR(DE3)pLysS Competent Cells

•2 × 2 ml4 × 2 mlSOC Medium

•2 ng2 ngTest Plasmid

Toxicity: Multiple Toxicity Values, refer to MSDS (O)

1. A. Roca (U. of Wisconsin), personal
communication.

2. Studier, F. W. (1991) J. Mol. Biol. 219,
37-44.

NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany